Immunic
IMUX
56 hedge funds and large institutions have $131M invested in Immunic in 2026 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 22 increasing their positions, 15 reducing their positions, and 31 closing their positions.
436% more call options, than puts
Call options by funds: $4.64M | Put options by funds: $865K
81% more capital invested
Capital invested by funds: $72.1M → $131M (+$58.6M)
47% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 15
12.63% more ownership
Funds ownership: 49.77% → 62.4% (+13%)
25% less funds holding
Funds holding: 75 → 56 (-19)
58% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
+$7.96M |
| 2 |
JHC
Jones Hill Capital
New York
|
+$6.66M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$4.62M |
| 4 |
Millennium Management
New York
|
+$4.47M |
| 5 |
LCM
Laurion Capital Management
New York
|
+$2.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$3.76M |
| 2 |
6CM
683 Capital Management
New York
|
-$1.21M |
| 3 |
Renaissance Technologies
New York
|
-$1.02M |
| 4 |
HF
HRT Financial
New York
|
-$547K |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$236K |
IMUX Hedge Fund Activity: Q2 2026 in Review
56 of the 8,350 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q2 2026, worth a combined $131M — up 81% from $72.1M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of IMUX and 13 opened new positions — a net loss of 18 holders — while 15 trimmed existing stakes and 22 added.
The largest buyer was Braidwell, opening a new position worth an estimated $7.96M. The largest seller was Morgan Stanley, cutting an estimated $3.76M.
- 56 institutional investors held Immunic (IMUX) as of Q2 2026, down from 75 in Q1 2026.
- Funds reported $131M of Immunic stock for Q2 2026, up 81% quarter-over-quarter.
- 13 funds opened new Immunic positions in Q2 2026 and 31 closed out, a net change of -18 holders.
- The largest Immunic buyer in Q2 2026 was Braidwell, an estimated $7.96M added.
- The largest Immunic seller in Q2 2026 was Morgan Stanley, an estimated $3.76M sold.
Based on aggregated 13F filings for Q2 2026.